ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Ocular Therapeutix Inc

Ocular Therapeutix Inc (OCUL)

9.10
-0.21
(-2.26%)
Closed March 29 04:00PM
9.08
-0.02
(-0.22%)
After Hours: 07:59PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
9.10
Bid
9.09
Ask
9.50
Volume
2,199,081
9.06 Day's Range 9.495
1.995 52 Week Range 11.31
Market Cap
Previous Close
9.31
Open
9.30
Last Trade
1
@
9.1
Last Trade Time
Financial Volume
$ 20,354,880
VWAP
9.2561
Average Volume (3m)
2,104,823
Shares Outstanding
148,627,439
Dividend Yield
-
PE Ratio
-19.00
Earnings Per Share (EPS)
-0.48
Revenue
51.49M
Net Profit
-71.04M

About Ocular Therapeutix Inc

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitation... Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Ocular Therapeutix Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker OCUL. The last closing price for Ocular Therapeutix was $9.31. Over the last year, Ocular Therapeutix shares have traded in a share price range of $ 1.995 to $ 11.31.

Ocular Therapeutix currently has 148,627,439 shares outstanding. The market capitalization of Ocular Therapeutix is $1.35 billion. Ocular Therapeutix has a price to earnings ratio (PE ratio) of -19.00.

OCUL Latest News

Form S-8 - Securities to be offered to employees in employee benefit plans

  As filed with the Securities and Exchange Commission on March 11, 2024   Registration No. 333-_____     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

http://fasb.org/us-gaap/2023#ProductMemberhttp://fasb.org/us-gaap/2023#ProductMemberhttp://fasb.org/us-gaap/2023#DerivativeLiabilitiesNoncurrent00http://fasb.org/us-gaap/2023#DerivativeLiabilitiesN...

Form 8-K - Current report

false 0001393434 0001393434 2024-03-11 2024-03-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED...

U.S. Index Futures Dip Ahead of Inflation Data and Oracle’s Earnings; Oil Prices Edge Higher

In Monday’s pre-market trading, U.S. index futures are indicating a downward move, following the worst week for the Dow Jones since October. Investors are keeping an eye on the important...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 3 - Initial statement of beneficial ownership of securities

  Exhibit 24   LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS   Know all by these presents, that the undersigned hereby makes, constitutes and...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.88-8.817635270549.9810.288.9712990689.55766876CS
4-1.05-10.344827586210.1511.318.8324287789.87063631CS
124.597.82608695654.611.313.759921048238.01861258CS
265.95188.8888888893.1511.311.99516120616.14956818CS
523.9978.08219178085.1111.311.99513135895.82360958CS
156-7.71-45.865556216516.8119.841.99510401356.90423452CS
2605.07125.8064516134.0324.31.9959725007.71757837CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

OCUL Discussion

View Posts
Monksdream Monksdream 3 weeks ago
OCUL 10Q due March 11
πŸ‘οΈ0
glenn1919 glenn1919 4 months ago
OCUL....................................https://stockcharts.com/h-sc/ui?s=OCUL&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
trendzone trendzone 1 year ago
Tard sells $6.00 call option at $0.15 at the close,apparently they were born yesterday.
πŸ‘οΈ0
glenn1919 glenn1919 1 year ago
OCUL..........................................https://stockcharts.com/h-sc/ui?s=OCUL&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
trendzone trendzone 1 year ago
Clueless fool sells $6.00 call option at $0.10 when they were just trading at $0.30,with the big rally going on in the stock today, what a total fool they are.
πŸ‘οΈ0
cuggegrosse cuggegrosse 1 year ago
I chose OCUL to invest in because the market conditions should not effect the PPS(much),plus I can sell covered calls and make some monthly cash,besides they have products that are in demand !!!!
👍️ 1
cuggegrosse cuggegrosse 1 year ago
Yes I have noticed that
👍️ 1
Tzr250rg Tzr250rg 1 year ago
Ask is super thin wont take much to move. GLTUA
πŸ‘οΈ0
cuggegrosse cuggegrosse 1 year ago
My eye doctor says Dextenza is a very good drug and he raccomends it !!!!!
👍️ 1
cuggegrosse cuggegrosse 1 year ago
DEXTENZA is doing very,very well,great revs expected in 2023
👍️ 1
cuggegrosse cuggegrosse 1 year ago
This company could go to $8.00 very eassy
👍️ 1
spotonge spotonge 1 year ago
boys need to wake up
πŸ‘οΈ0
biotechslayr biotechslayr 2 years ago
Is anyone at all following OCUL into the end of the months binary? TKI data could be a game changer. Total TAM is ridiculous (look at REGN mcap!)
👍️ 1
oxnous oxnous 3 years ago
OCUL --charting


πŸ‘οΈ0
oxnous oxnous 3 years ago
With the aging population, eye care is becoming an increasing concern. Dry eye, glaucoma, macular degeneration etc. will be expanding market sub sectors
πŸ‘οΈ0
ClayTrader ClayTrader 3 years ago
* * $OCUL Video Chart 04-29-2021 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
whytestocks whytestocks 3 years ago
Just In: $OCUL Ocular Therapeutix Announces Receipt of a Permanent Category I CPT Code from the American Medical Association for the Insertion of Intracanalicular Inserts

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that its application for the creation of a Category I Current Procedural Ter...

In case you are interested OCUL - Ocular Therapeutix Announces Receipt of a Permanent Category I CPT Code from the American Medical Association for the Insertion of Intracanalicular Inserts
πŸ‘οΈ0
whytestocks whytestocks 3 years ago
Breaking News: $OCUL Ocular Therapeutix(TM) Announces Topline Phase 1 Clinical Trial Results of OTX-CSI

OTX-CSI demonstrates improvement in signs and symptoms of Dry Eye Disease Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the ey...

Got this from OCUL - Ocular Therapeutix(TM) Announces Topline Phase 1 Clinical Trial Results of OTX-CSI
πŸ‘οΈ0
TheFinalCD TheFinalCD 3 years ago
OCUL 10.87 NEW HIGH OF DAY
πŸ‘οΈ0
whytestocks whytestocks 3 years ago
Just In: $OCUL Ocular Therapeutix Announces Preliminary Net Product Revenue of $5.8 Million to $5.9 Million for Third Quarter 2020, Representing Greater Than a 250% Increase Over the Previous Quarter

Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported preliminary, unaudited net product revenue for the third quarter ended Septe...

Find out more OCUL - Ocular Therapeutix Announces Preliminary Net Product Revenue of $5.8 Million to $5.9 Million for Third Quarter 2020, Representing Greater Than a 250% Increase Over the Previous Quarter
πŸ‘οΈ0
now invest now invest 4 years ago
Thus far OCUL is trading nicely!!
πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $OCUL Video Chart 05-22-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $OCUL Video Chart 03-04-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
edwardport edwardport 4 years ago
near term 10% projected increase in market price

closed on 2/7/20 @ $5.21
πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $OCUL Video Chart 02-07-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $OCUL Video Chart 01-03-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $OCUL Video Chart 11-29-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
TFMG TFMG 5 years ago
OCUL - POSSIBLE 25% TREND MOVE ON THE DAILY

Ocular Therapeutix , Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

SHORT INTEREST
8.24M 07/15/19

P/E Current
-2.78

P/E Ratio (with extraordinary items)
-2.92

Average Recommendation: OVERWEIGHT

Average Target Price: 9.67

πŸ‘οΈ0
tste9 tste9 5 years ago
Great news! BUT, hoped for more volume price etc. wow
GLA
πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $OCUL Video Chart 07-26-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
whytestocks whytestocks 5 years ago
News: $OCUL Ocular Therapeutix(TM) Announces Early Assignment of Permanent and Specific J-Code (J1096) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg by the Centers for Medicare and Medicaid Services

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a ...

Got this from Ocular Therapeutix(TM) Announces Early Assignment of Permanent and Specific J-Code (J1096) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg by the Centers for Medicare and Medicaid Services
πŸ‘οΈ0
smallbio smallbio 5 years ago

Is DEXTENZA currently only targeting medicare patients, as there is no private insurance company will reimburse the cost?
πŸ‘οΈ0
tste9 tste9 5 years ago
What is up with this little piggy, lately! #&*#@*
πŸ‘οΈ0
tste9 tste9 5 years ago
Great news thanks for post. Do you know of any web site that posts OCUL sales per week. Thank you. GL
πŸ‘οΈ0
whytestocks whytestocks 5 years ago
News: $OCUL Ocular Therapeutix(TM) Announces Commercial Launch of DEXTENZA® (dexamethasone intracanalicular insert) 0.4 mg for Ophthalmic Use in the United States

Pass-through payment status and C-code from the Centers for Medicare and Medicaid Services (CMS) now active Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and ...

In case you are interested https://marketwirenews.com/news-releases/ocular-therapeutix-tm-announces-commercial-launch-of-dextenza-x-8439742.html
πŸ‘οΈ0
swingingRichard swingingRichard 5 years ago
Shorted 10,000 shares. Looking good.
πŸ‘οΈ0
tste9 tste9 5 years ago
Shorts ease out as usual. criminal how shorts manipulate SP then just slither out unharmed. GLA
πŸ‘οΈ0
tste9 tste9 5 years ago
YEA BABY!
πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $OCUL Video Chart 06-21-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
whytestocks whytestocks 5 years ago
News: $OCUL Ocular Therapeutix(TM) Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (0.4 Dexamethasone Intracanalicular Insert for Ophthalmic Use) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery

DEXTENZA ® Now Approved for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases...

Find out more https://marketwirenews.com/news-releases/ocular-therapeutix-tm-announces-fda-approval-of-supplemental-new-drug-application-snda-for-dextenza-xae-0-4-dexamethasone-intracanalicular-insert-for-ophthalmic-use-for-the-treatment-of-ocular-inflammation-following-ophthalmic-surgery-8394606.html
πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $OCUL Video Chart 06-11-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
Tzr250rg Tzr250rg 5 years ago
low volume today
πŸ‘οΈ0
whytestocks whytestocks 5 years ago
News: $OCUL Ocular Therapeutix(TM) Announces Receipt of C-Code and Pass-Through Payment Status for DEXTENZA®

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved t...

Got this from https://marketwirenews.com/news-releases/ocular-therapeutix-tm-announces-receipt-of-c-code-and-pass-through-payment-status-for-dextenza-xae--8261962.html
πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $OCUL Video Chart 05-21-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
now invest now invest 5 years ago
Stopped in to see anything up.... oh well...
πŸ‘οΈ0
RolandDoe RolandDoe 5 years ago
Hardly
πŸ‘οΈ0
Rakbors Rakbors 5 years ago
No
πŸ‘οΈ0
RickieK RickieK 5 years ago
Hellooooo is there anyone here
πŸ‘οΈ0
now invest now invest 5 years ago
Thought there would be more messages here..... been buying On Raymond James recommendation.... they have it as a strong buy with a target of 11 !!!!!! Ok with me that the stock isn't moving as I add!! LOL.
πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $OCUL Video Chart 02-22-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock